"Diabetes is a progressive disease; a short course of BG-319 might permanently reverse it for over 96 million people in the United States."
BG-319 holds tremendous potential to reverse pre-diabetes in 96 million Americans and help over 15 million Americans with diabetes, who struggle with current dugs, achieve glycemic control.
BG-319
BG-319 is a New Molecular Entity that lowers blood sugar by correcting the muscles' ability to take up and store sugar as glycogen. BG-319 works independently of insulin, during insulin resistance, and at all stages of diabetes.
BG-319 does the primary job of insulin. As a result, BG-319 reduces circulating insulin and the amount of exogenous insulin that has to be injected.
A single course of BG-319 results in long-term reductions in blood glucose after stopping the drug, indicating BG-319 has the potential to reverse prediabetes and diabetes.
BG-319 lowers blood glucose when all other drugs fail
The figure, BG-319 compared to current drugs: Average blood glucose in mice with type-1 diabetes before (circles, Controls) and three hours after (triangles, Treated) an oral dose of the shown interventions. Each shape represents a blood glucose reading from a single animal. Error bars show 95% CI.